Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not previously received chemotherapy for metastatic NSCLC, regardless of PD-L1 expression and EGFR or ALK genomic alteration status.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-06, Vol.378 (24), p.2288-2301
Hauptverfasser:	Socinski, Mark A, Jotte, Robert M, Cappuzzo, Federico, Orlandi, Francisco, Stroyakovskiy, Daniil, Nogami, Naoyuki, Rodríguez-Abreu, Delvys, Moro-Sibilot, Denis, Thomas, Christian A, Barlesi, Fabrice, Finley, Gene, Kelsch, Claudia, Lee, Anthony, Coleman, Shelley, Deng, Yu, Shen, Yijing, Kowanetz, Marcin, Lopez-Chavez, Ariel, Sandler, Alan, Reck, Martin
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anaplastic Lymphoma Kinase Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis B7-H1 Antigen - antagonists & inhibitors Bevacizumab Bevacizumab - administration & dosage Cancer therapies Carboplatin Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - secondary Chemotherapy Death Epidermal growth factor receptors Female Genes, erbB-1 Genotypes Humans Immunosuppression Immunotherapy Liver Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Lymphocytes T Male Medical prognosis Metastases Metastasis Middle Aged Monoclonal antibodies Motivation Mutation Neoplasm Metastasis - drug therapy Non-small cell lung carcinoma Oncology Paclitaxel Paclitaxel - administration & dosage Patients PD-L1 protein Population Receptor Protein-Tyrosine Kinases - genetics Survival Analysis Targeted cancer therapy Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not previously received chemotherapy for metastatic NSCLC, regardless of PD-L1 expression and EGFR or ALK genomic alteration status.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1716948